An interactive tool highlighting the disease burden, impact and management of prurigo nodularis throughout the patient journey before diagnosis, during diagnosis and during treatment.
Explore 3 interactive patient cases to learn more about the signs, symptoms, and burden of atopic dermatitis.
Diagnose the patients based on a variety of cases and presentations based on American Academy of Dermatology (AAD) criteria and assess their disease severity
Blisters and Beyond: Autoimmunity Meets Type 2 Inflammation in Bullous Pemphigoid
Dermatology
Join Dr. Victoria Werth in exploring the clinical presentation of BP and how type 2 inflammation contributes to the development of disease signs and symptoms
ESPGHAN 2024 | Shedding Light on Pediatric Eosinophilic Esophagitis: Timely Identification and Management
Gastroenterology
Prof. Salvatore Oliva and Dr. Dhandapani Ashok discuss the burden of type 2 inflammation in pediatric EoE and the importance of early diagnosis and management.
ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.
For healthcare professionals in Algeria: Please read the additional Terms of Use.
Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.